A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.

被引：0

作者：

Middleton, Gary William

Valle, Juan W.

Wadsley, Jonathan

Propper, David

Coxon, Fareeda Y.

Ross, Paul J.

Madhusudan, Srinivasan

Roques, Tom

Cunningham, David

Corrie, Philippa

Greenhalf, William

Shaw, Victoria

Cox, Trevor F.

Silcocks, Paul

Nanson, Gemma

Neoptolemos, John P.

机构：

[1] Univ Birmingham, Birmingham, W Midlands, England

[2] Christie Hosp NHS Fdn Trust, European ENETS Ctr Excellence, Manchester, Lancs, England

[3] Weston Pk Hosp, Dept Clin Oncol, Sheffield, S Yorkshire, England

[4] St Bartholomews Hosp, Inst Canc, Ctr Med Oncol, London, England

[5] Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England

[6] Guys & St Thomas NHS Fdn Trust, London, England

[7] Univ Nottingham Hosp, Sch Mol Med Sci, Nottingham NG7 2UH, England

[8] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England

[9] Royal Marsden Hosp NHS Fdn Trust, London, England

[10] Addenbrookes Hosp, Ctr Oncol, Cambridge, England

[11] Univ Liverpool, Liverpool L69 3BX, Merseyside, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4004

引用

页数：1

共 50 条

[1] A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.
Middleton, Gary William
Valle, Juan W.
Wadsley, Jonathan
Propper, David
Coxon, Fareeda Y.
Ross, Paul J.
Madhusudan, Srinivasan
Roques, Tom
Cunningham, David
Corrie, Philippa
Greenhalf, William
Shaw, Victoria
Cox, Trevor F.
Silcocks, Paul
Nanson, Gemma
Neoptolemos, John P.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Middleton, Gary
Silcocks, Paul
Cox, Trevor
Valle, Juan
Wadsley, Jonathan
Propper, David
Coxon, Fareeda
Ross, Paul
Madhusudan, Srinivasan
Roques, Tom
Cunningham, David
Falk, Stephen
Wadd, Nick
Harrison, Mark
Corrie, Pippa
Iveson, Tim
Robinson, Angus
McAdam, Karen
Eatock, Martin
Evans, Jeff
Archer, Caroline
Hickish, Tamas
Garcia-Alonso, Angel
Nicolson, Marianne
Steward, William
Anthoney, Alan
Greenhalf, William
Shaw, Victoria
Costello, Eithne
Naisbitt, Dean
Rawcliffe, Charlotte
Nanson, Gemma
Neoptolemos, John
LANCET ONCOLOGY, 2014, 15 (08): : 829 - 840
[3] Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.
Neoptolemos, John P.
Greenhalf, William
Cox, Trevor F.
Costello, Eithne
Shaw, Victoria
Valle, Juan W.
Coxon, Fareeda Y.
Wadsley, Jonathan
Propper, David
Ross, Paul J.
Madhusudan, Srinivasan
Roques, Tom
Cunningham, David
Eatock, Martin McKinlay
Iveson, Tom
Patel, Kinnari
Garcia-Alonso, Angel
Nanson, Gemma
Middleton, Gary
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
Staff, Caroline
Mozaffari, Fariba
Frodin, Jan-Erik
Mellstedt, Hakan
Liljefors, Maria
INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (03) : 1293 - 1303
[5] A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC)
Buanes, T.
Maurel, J.
Liauw, W.
Hebbar, M.
Nemunaitis, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[6] A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer.
Stathopoulos, GP
Aravantinos, G
Syrigos, K
Kalbakis, K
Karvounis, N
Papakotoulas, P
Boukovinas, J
Potamianou, A
Polyzos, A
Christophilakis, CH
Georgoulias, V
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
[7] A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
Hong Suk Song
Young Rok Do
Heung Moon Chang
Min Hee Ryu
Kyung Hee Lee
Yeul Hong Kim
Dae Sik Hong
Jae Yong Cho
Kyoung Eun Lee
Si Young Kim
Cancer Chemotherapy and Pharmacology, 2008, 62 : 763 - 768
[8] A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
Song, Hong Suk
Do, Young Rok
Chang, Heung Moon
Ryu, Min Hee
Lee, Kyung Hee
Kim, Yeul Hong
Hong, Dae Sik
Cho, Jae Yong
Lee, Kyoung Eun
Kim, Si Young
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 763 - 768
[9] KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.
Jo, Jung Hyun
Kim, Yong-Tae
Choi, Ho Soon
Kim, Ho Gak
Lee, Hong Sik
Choi, Young Woo
Kim, Dong Uk
Lee, Kwang Hyuck
Kim, Eui Joo
Han, Jeong Ho
Lee, Seung Ok
Park, Chang-Hwan
Choi, Eun Kwang
Lee, Kyong Joo
Cho, Jae Yong
Lee, Woo Jin
Song, Si Young
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Cunningham, David
Chau, Ian
Stocken, Deborah D.
Valle, Juan W.
Smith, David
Steward, William
Harper, Peter G.
Dunn, Janet
Tudur-Smith, Catrin
West, Julia
Falk, Stephen
Crellin, Adrian
Adab, Fawzi
Thompson, Joyce
Leonard, Pauline
Ostrowski, Joe
Eatock, Martin
Scheithauer, Werner
Herrmann, Richard
Neoptolemos, John P.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5513 - 5518

← 1 2 3 4 5 →